Drug Profile
Research programme: malaria vaccine - Institut Pasteur/Sanofi
Latest Information Update: 08 Apr 2022
Price :
$50
*
At a glance
- Originator sanofi pasteur
- Developer Sanofi
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Malaria in France (Parenteral)
- 22 Oct 2008 Sanofi-aventis and Medicines for Malaria Venture enter into a collaboration to accelerate research and development of new antimalarial drugs
- 15 Oct 2007 sanofi pasteur establishes a collaborative partnership with Institut Pasteur for the development of a malaria vaccine